Enovix Posts Zero Revenue, Narrows Q2 Net Loss to $50.2M

Ticker: ENVX · Form: 10-Q · Filed: 2025-07-31T00:00:00.000Z

Sentiment: bearish

Topics: Battery Technology, Pre-Revenue, High Growth Potential, R&D Intensive, Speculative Investment, Silicon Anode, Energy Storage

Related Tickers: ENVX

TL;DR

**ENVX is still burning cash with no revenue, making it a high-risk bet on future battery tech.**

AI Summary

Enovix Corp reported no revenue for the three and six months ended June 29, 2025, consistent with the prior year periods. The company's net loss for the three months ended June 29, 2025, was $50.2 million, a decrease from a net loss of $55.8 million for the same period in 2024. For the six months ended June 29, 2025, the net loss was $105.1 million, compared to a net loss of $108.9 million in the prior year. Research and development expenses were $35.1 million for the three months ended June 29, 2025, down from $38.7 million in 2024, and $72.8 million for the six months, down from $75.3 million. Selling, general, and administrative expenses increased to $15.1 million for the three months ended June 29, 2025, from $14.9 million in 2024, and to $32.3 million for the six months from $31.8 million. The company's strategic outlook remains focused on the development and commercialization of its advanced silicon-anode lithium-ion batteries, with ongoing investments in manufacturing capabilities and intellectual property. Enovix continues to face risks associated with its pre-revenue stage and reliance on future product commercialization.

Why It Matters

This filing highlights Enovix's continued pre-revenue status, which is critical for investors evaluating its long-term viability and cash burn. While the net loss narrowed, the absence of revenue indicates the company is still in a heavy investment phase, relying on its cash reserves to fund R&D and manufacturing scale-up. For employees, this means job security is tied to successful product commercialization and continued funding. Customers, particularly in the mobile and EV sectors, are keenly watching for the delivery of high-performance silicon-anode batteries that could disrupt the competitive landscape dominated by traditional lithium-ion battery makers.

Risk Assessment

Risk Level: high — The risk level is high because Enovix reported no revenue for the three and six months ended June 29, 2025, and incurred net losses of $50.2 million and $105.1 million, respectively. This pre-revenue stage, coupled with significant R&D expenses of $72.8 million for the six months, indicates a substantial reliance on capital raises and successful future commercialization, presenting considerable financial uncertainty.

Analyst Insight

Investors should approach ENVX with extreme caution, recognizing it as a speculative growth play. Monitor progress on manufacturing scale-up and customer engagements closely, as any delays could significantly impact its cash runway and valuation. Consider a small, diversified position if you have a high-risk tolerance and a long-term horizon for disruptive battery technology.

Financial Highlights

debt To Equity: N/A
revenue: $0
operating Margin: N/A
total Assets: N/A
total Debt: N/A
net Income: -$50.2M
eps: N/A
gross Margin: N/A
cash Position: N/A
revenue Growth: N/A

Key Numbers

$0 — Revenue (No revenue reported for Q2 2025 or H1 2025, indicating pre-commercialization stage.)
-$50.2M — Net Loss (Q2 2025) (Net loss narrowed from -$55.8M in Q2 2024, showing some cost management.)
-$105.1M — Net Loss (H1 2025) (Net loss for the first half narrowed from -$108.9M in H1 2024.)
$72.8M — R&D Expenses (H1 2025) (Significant investment in research and development, down from $75.3M in H1 2024.)
$32.3M — SG&A Expenses (H1 2025) (Selling, general, and administrative expenses increased from $31.8M in H1 2024.)

Key Players & Entities

Enovix Corp (company) — filer of the 10-Q
$50.2 million (dollar_amount) — net loss for the three months ended June 29, 2025
$55.8 million (dollar_amount) — net loss for the three months ended June 30, 2024
$105.1 million (dollar_amount) — net loss for the six months ended June 29, 2025
$108.9 million (dollar_amount) — net loss for the six months ended June 30, 2024
$35.1 million (dollar_amount) — research and development expenses for the three months ended June 29, 2025
$38.7 million (dollar_amount) — research and development expenses for the three months ended June 30, 2024
$72.8 million (dollar_amount) — research and development expenses for the six months ended June 29, 2025
$75.3 million (dollar_amount) — research and development expenses for the six months ended June 30, 2024
Bloomberg (company) — publisher of the analysis

FAQ

What was Enovix Corp's revenue for the second quarter of 2025?

Enovix Corp reported no revenue for the three months ended June 29, 2025, consistent with the prior year period.

How did Enovix's net loss change in Q2 2025 compared to Q2 2024?

Enovix's net loss for the three months ended June 29, 2025, was $50.2 million, a decrease from a net loss of $55.8 million for the same period in 2024.

What were Enovix's research and development expenses for the first half of 2025?

Research and development expenses for Enovix were $72.8 million for the six months ended June 29, 2025, down from $75.3 million in the prior year period.

What is Enovix Corp's current business stage?

Enovix Corp is currently in a pre-revenue stage, focusing on the development and commercialization of its advanced silicon-anode lithium-ion batteries, as evidenced by zero revenue and significant R&D expenses.

What are the primary risks for Enovix Corp investors?

Primary risks for Enovix Corp investors include its pre-revenue status, substantial net losses, and reliance on future product commercialization and capital raises to fund ongoing operations and manufacturing scale-up.

How much did Enovix spend on selling, general, and administrative expenses in Q2 2025?

Enovix spent $15.1 million on selling, general, and administrative expenses for the three months ended June 29, 2025, an increase from $14.9 million in the same period of 2024.

What is Enovix's strategic focus based on this 10-Q filing?

Enovix's strategic focus remains on the development and commercialization of its advanced silicon-anode lithium-ion batteries, with continued investments in manufacturing capabilities and intellectual property.

Did Enovix Corp report any changes in its common stock or warrants during the period?

The filing indicates changes in common stock and warrants from December 30, 2024, to June 29, 2025, reflecting ongoing equity activities, though specific details of share counts are not in the provided summary.

What is the significance of Enovix's accumulated other comprehensive income?

Enovix's accumulated other comprehensive income is a component of equity, showing changes from December 29, 2024, to June 29, 2025, which can reflect unrealized gains or losses on certain financial instruments.

Why is Enovix Corp considered a high-risk investment?

Enovix Corp is considered a high-risk investment due to its lack of revenue, significant operating losses, and the inherent uncertainties associated with bringing a new technology to market and scaling manufacturing operations.

Risk Factors

Pre-Revenue Stage and Cash Burn [high — financial]: Enovix Corp reported no revenue for the three and six months ended June 29, 2025. The company incurred a net loss of $50.2 million for Q2 2025 and $105.1 million for H1 2025, indicating a significant cash burn rate while in the pre-commercialization phase. This reliance on future product sales presents a substantial financial risk.
Manufacturing Scale-Up Challenges [high — operational]: The company's strategic outlook emphasizes investments in manufacturing capabilities for its advanced silicon-anode lithium-ion batteries. Scaling up production to meet anticipated demand, while maintaining quality and cost-efficiency, poses significant operational risks. Delays or inefficiencies in manufacturing could impact commercialization timelines.
Competition in Battery Technology [medium — market]: The lithium-ion battery market is highly competitive, with established players and emerging technologies. Enovix faces the risk of being outpaced by competitors in terms of technological advancements, cost, or market adoption. Successful commercialization depends on differentiating its silicon-anode technology and capturing market share.
Reliance on Future Funding [high — financial]: Given the lack of revenue and ongoing operational expenses, Enovix is likely reliant on continued access to capital markets or strategic partnerships to fund its operations and growth initiatives. Any disruption in funding could severely impact its ability to execute its business plan.
Intellectual Property Protection [medium — legal]: Enovix's business model relies heavily on its proprietary silicon-anode technology. Protecting its intellectual property through patents and trade secrets is crucial. Infringement by competitors or challenges to its IP could significantly harm its competitive advantage and future revenue streams.

Industry Context

Enovix operates in the highly competitive and rapidly evolving battery technology sector, specifically focusing on advanced lithium-ion solutions. The industry is driven by increasing demand for higher energy density, faster charging, and improved safety in applications ranging from consumer electronics to electric vehicles and energy storage. Key trends include the development of next-generation battery chemistries and materials, such as silicon anodes, to overcome the limitations of current technologies.

Regulatory Implications

As a company developing advanced materials and manufacturing processes, Enovix may face regulatory scrutiny related to environmental compliance, safety standards for battery production, and intellectual property rights. Compliance with evolving regulations in these areas is critical for sustained operations and market access.

What Investors Should Do

[object Object]
[object Object]
[object Object]
[object Object]

Key Dates

2025-06-29: End of Q2 2025 Reporting Period — No revenue reported, net loss of $50.2 million, R&D expenses of $35.1 million, SG&A expenses of $15.1 million.
2024-06-29: End of Q2 2024 Reporting Period — No revenue reported, net loss of $55.8 million, R&D expenses of $38.7 million, SG&A expenses of $14.9 million.
2025-07-31: Filing Date of 10-Q — Provides the latest financial and operational update to investors and the public.

Glossary

Silicon-anode lithium-ion batteries: A type of rechargeable battery that uses silicon as the anode material, aiming to provide higher energy density and faster charging compared to traditional graphite anodes. (This is Enovix's core technology, central to its commercialization strategy and competitive differentiation.)
Pre-revenue stage: A phase in a company's lifecycle where it has not yet generated any sales revenue from its products or services. (Enovix is currently in this stage, highlighting its reliance on future product launches and market adoption for financial viability.)
Research and development (R&D) expenses: Costs incurred by a company in the process of developing new products, services, or improving existing ones. (Enovix continues to invest heavily in R&D, indicating its commitment to technological advancement and innovation in battery technology.)
Selling, general, and administrative (SG&A) expenses: Costs associated with marketing, selling, and distributing a company's products, as well as general overhead and administrative functions. (An increase in SG&A suggests growing operational costs as the company prepares for commercialization, though the increase is modest.)

Year-Over-Year Comparison

Compared to the prior year periods, Enovix Corp reported no revenue for the three and six months ended June 29, 2025, mirroring the previous year. The net loss for Q2 2025 decreased to $50.2 million from $55.8 million in Q2 2024, and the H1 2025 net loss narrowed to $105.1 million from $108.9 million. R&D expenses saw a slight reduction, while SG&A expenses experienced a modest increase, indicating ongoing cost management efforts alongside continued investment in technology development.

From the Filing

0001828318-25-000275.txt : 20250731 0001828318-25-000275.hdr.sgml : 20250731 20250731170923 ACCESSION NUMBER: 0001828318-25-000275 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 83 CONFORMED PERIOD OF REPORT: 20250629 FILED AS OF DATE: 20250731 DATE AS OF CHANGE: 20250731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enovix Corp CENTRAL INDEX KEY: 0001828318 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] ORGANIZATION NAME: 04 Manufacturing EIN: 853174357 FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39753 FILM NUMBER: 251172652 BUSINESS ADDRESS: STREET 1: 3501 W. WARREN AVENUE CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 510 695-2350 MAIL ADDRESS: STREET 1: 3501 W. WARREN AVENUE CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: Rodgers Silicon Valley Acquisition Corp DATE OF NAME CHANGE: 20201014 10-Q 1 envx-20250629.htm 10-Q envx-20250629 0001828318 December 28 2025 Q2 false 267 xbrli:shares iso4217:USD iso4217:USD xbrli:shares envx:segment xbrli:pure utr:sqft envx:plaintiff envx:award envx:family_member utr:D 0001828318 2024-12-30 2025-06-29 0001828318 us-gaap:CommonStockMember 2024-12-30 2025-06-29 0001828318 us-gaap:WarrantMember 2024-12-30 2025-06-29 0001828318 2025-07-28 0001828318 2025-06-29 0001828318 2024-12-29 0001828318 2025-03-31 2025-06-29 0001828318 2024-04-01 2024-06-30 0001828318 2024-01-01 2024-06-30 0001828318 us-gaap:CommonStockMember 2024-12-29 0001828318 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 0001828318 us-gaap:RetainedEarningsMember 2024-12-29 0001828318 us-gaap:ParentMember 2024-12-29 0001828318 us-gaap:NoncontrollingInterestMember 2024-12-29 0001828318 us-gaap:RetainedEarningsMember 2024-12-30 2025-03-30 0001828318 us-gaap:ParentMember 2024-12-30 2025-03-30 0001828318 us-gaap:NoncontrollingInterestMember 2024-12-30 2025-03-30 0001828318 2024-12-30 2025-03-30 0001828318 us-gaap:CommonStockMember 2024-12-30 2025-03-30 0001828318 us-gaap:AdditionalPaidInCapitalMember 2024-12-30 2025-03-30 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-30 2025-03-30 0001828318 us-gaap:CommonStockMember 2025-03-30 0001828318 us-gaap:AdditionalPaidInCapitalMember 2025-03-30 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-30 0001828318 us-gaap:RetainedEarningsMember 2025-03-30 0001828318 us-gaap:ParentMember 2025-03-30 0001828318 us-gaap:NoncontrollingInterestMember 2025-03-30 0001828318 2025-03-30 0001828318 us-gaap:RetainedEarningsMember 2025-03-31 2025-06-29 0001828318 us-gaap:ParentMember 2025-03-31 2025-06-29 0001828318 us-gaap:NoncontrollingInterestMember 2025-03-31 2025-06-29 0001828318 us-gaap:CommonStockMember 2025-03-31 2025-06-29 0001828318 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 2025-06-29 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 2025-06-29 0001828318 us-gaap:CommonStockMember 2025-06-29 0001828318 us-gaap:AdditionalPaidInCapitalMember 2025-06-29 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-29 0001828318 us-gaap:RetainedEarningsMember 2025-06-29 0001828318 us-gaap:ParentMember 2025-06-29 0001828318 us-gaap:NoncontrollingInterestMember 2025-06-29 0001828318 us-gaap:CommonStockMember 2023-12-31 0001828318 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001828318 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001828318 us-gaap:RetainedEarningsMember 2023-12-31 0001828318 us-gaap:ParentMember 2023-12-31 0001828318 us-gaap:NoncontrollingInterestMember 2023-12-31 0001828318 2023-12-31 0001828318 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001828318 us-gaap:ParentMember 2024-01-01 2024-03-31 0001828318 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001828318 2024-01-01 2024-03-31 0001828318 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001828318 us-gaap:Additio